Prostate Cancer Canada’s Step Up Challenge in Calgary raises $170,000
Corporate Calgary raised funds for prostate cancer research by racing up 5 skyscrapers.
Calgary, AB – March 1, 2015 – On Sunday, March 1, Calgary’s corporate community raised more than $170,000 for Prostate Cancer Canada (PCC) in the second annual Step Up Challenge, presented by Scotiabank. Twenty teams of five were challenged to climb 5,000ft of stairs while raising a minimum of $5,000.
Prostate Cancer Canada’s Step Up Challenge in Vancouver raises $150,000
Corporate Vancouver raised funds for prostate cancer research by racing up 5 skyscrapers.
Vancouver, BC – February 23, 2015 – On Sunday, February 22, Vancouver’s corporate community raised more than $150,000 for Prostate Cancer Canada (PCC) in the second annual Step Up Challenge, presented by Scotiabank. Twenty five teams of five were challenged to climb 5,000ft of stairs while raising a minimum of $5,000.
“You’re Hired!” Says Building Trades of Alberta to New Research “Apprentice”
EDMONTON, January 20th, 2015 - Prostate Cancer Canada and the Building Trades of Alberta today announced new funding that will support groundbreaking research into advanced stage prostate cancer. The funding is described as an “apprenticeship” – a unique opportunity for a talented young researcher to work on leading-edge research with the best equipment and alongside the brightest minds.
Prostate Cancer Canada reminds men that early detection using ‘Smart Screening’ for prostate cancer can save lives
Toronto, ON – October 27, 2014 – Prostate Cancer Canada responds today to guidelines released from The Canadian Task Force on Preventive Health Care (CTFPHC) recommending that the Prostate Specific Antigen (PSA) test should be eliminated as a screening tool for prostate cancer. Prostate Cancer Canada disagrees with the recommendations and wants to remind Canadians that when performed appropriately, the benefits of PSA screening far outweigh the negatives. According to new research based on modelling estimates, if PSA testing was eliminated, the cases of advanced (metastatic) prostate cancer would double, resulting in an estimated 13-20 per cent increase in prostate cancer deaths annually.[i]